Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9428551-B2
Publication Date
2016-08-30
Expiration Date
Abstract
The present invention provides novel therapeutic antimicrobial peptides that are bactericides and have an inhibitory effect on biofilms produced by biofilm-forming bacteria and especially biofilm-forming Staphyloccocal bacteria. The invention includes the nucleic acids encoding the polypeptides, methods of treating bacterial infections, medical devices or implants or prosthetics impregnated with, covered or coated in the polypeptides, and means of delivery of the peptide to the oral cavity.
Core Innovation
The disclosure relates to antimicrobial peptides, including a bactericidal peptide comprising a peptide sequence QSFEWIYKQIKKLWA (SEQ ID NO:1), and isolated or recombinant polypeptides that comprise the same sequence or variants thereof having at least 90% identity to SEQ ID NO:1. These isolated or recombinant polypeptides are described as bactericidal and as having inhibitory activity against biofilm formation by biofilm-producing bacteria.
The document further describes nucleic acids encoding the disclosed isolated or recombinant polypeptides, and variants with defined sequence identity. The peptides and related compositions are presented as acting on biofilm-forming bacteria, with particular reference to Staphylococcal biofilm-forming bacteria, including Staphylococcus epidermidis and clinical isolates.
A mechanistic basis is also described in terms of a non-lytic killing process, including membrane depolarization and potassium and ATP efflux, as well as experimental evidence of antibiofilm activity and bactericidal properties across a set of pathogens and clinical isolates.
Claims Coverage
The provided independent claims cover two linked inventive concepts: a defined bactericidal isolated or recombinant polypeptide (with at least 90% identity to SEQ ID NO:1), and the use of the same class of polypeptides to inhibit biofilm formation by a biofilm-producing bacterium. Across the provided set, the main inventive requirements are sequence identity to SEQ ID NO:1 and specified biological effects (bactericidal activity and biofilm inhibition).
Defined bactericidal isolated or recombinant polypeptide with at least 90% identity to SEQ ID NO:1
An isolated or recombinant polypeptide comprising a peptide sequence QSFEWIYKQIKKLWA (SEQ ID NO:1) or a variant thereof having at least 90% identity to SEQ ID NO:1, wherein the isolated or recombinant polypeptide is bactericidal.
Biofilm formation inhibition by a defined isolated or recombinant polypeptide
An isolated or recombinant polypeptide comprising a peptide sequence QSFEWIYKQIKKLWA (SEQ ID NO:1) or a variant thereof having at least 90% identity to SEQ ID NO:1, wherein the isolated or recombinant polypeptide has an inhibitory effect on biofilm formation by a biofilm-producing bacterium.
The claim coverage provided is grounded in the peptide sequence QSFEWIYKQIKKLWA (SEQ ID NO:1) and sequence-identity-based variants, combined with two biological functional outcomes: bactericidal activity and inhibition of biofilm formation by biofilm-producing bacteria. Dependent claim fragments described in the provided content include nucleic acids encoding the polypeptide and specific application contexts such as oral or dental infection treatment, as well as surfaces impregnated or coated with the polypeptide.
Stated Advantages
Bactericidal activity for the disclosed isolated or recombinant polypeptides.
Inhibitory effect on biofilm formation by a biofilm-producing bacterium.
Stated focus on inhibiting Staphylococcal biofilm formation.
Documented Applications
Treatment of an oral or dental infection using the isolated or recombinant polypeptide comprising QSFEWIYKQIKKLWA (SEQ ID NO:1) or a variant having at least 90% identity.
Plastics or metal surfaces impregnated, coated, or covered with the isolated or recombinant polypeptide.
Interested in licensing this patent?